开云app官网登录入口网页版-官方正版

#ARVO#

17篇内容 | 1016人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1993322, encodeId=969f1993322a6, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=辉瑞的DMD基因疗法fordadistrogene movaparvovec在患者死亡后被FDA搁置, objectType=article, longId=292791, objectId=e037292e9125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e037292e9125, replyNumber=0, likeNumber=112, createdTime=2022-04-03, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e037292e9125, moduleTitle=辉瑞的DMD基因疗法fordadistrogene movaparvovec在患者死亡后被FDA搁置, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e037292e9125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993321, encodeId=d8c61993321cd, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验, objectType=article, longId=209670, objectId=f8062096e0cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8062096e0cf, replyNumber=0, likeNumber=74, createdTime=2022-01-18, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8062096e0cf, moduleTitle=Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f8062096e0cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993319, encodeId=5bea1993319d4, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=基因疗法Valoctocogene Roxaparvovec治疗严重血友病A：长期数据再次验证有效性和安全性, objectType=article, longId=195113, objectId=8ff319511304, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ff319511304, replyNumber=0, likeNumber=73, createdTime=2021-04-19, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ff319511304, moduleTitle=基因疗法Valoctocogene Roxaparvovec治疗严重血友病A：长期数据再次验证有效性和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8ff319511304)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993320, encodeId=cb9d19933202c, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=WFH 2020：四年数据显示，A型血友病基因疗法valoctocogene roxaparvovec可持续减少出血, objectType=article, longId=196108, objectId=e997196108f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e997196108f4, replyNumber=0, likeNumber=80, createdTime=2021-02-15, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e997196108f4, moduleTitle=WFH 2020：四年数据显示，A型血友病基因疗法valoctocogene roxaparvovec可持续减少出血, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e997196108f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993317, encodeId=7b92199331e49, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=2019年ARVO：Aflibercept能够长期改善黄斑变性的临床症状, objectType=article, longId=165443, objectId=df6916544389, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df6916544389, replyNumber=0, likeNumber=63, createdTime=2019-07-11, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df6916544389, moduleTitle=2019年ARVO：Aflibercept能够长期改善黄斑变性的临床症状, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=df6916544389)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993318, encodeId=171819933185e, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=2019年ARVO：青光眼长期治疗取得新进展, objectType=article, longId=165450, objectId=141116545004, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=141116545004, replyNumber=0, likeNumber=82, createdTime=2019-06-05, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=141116545004, moduleTitle=2019年ARVO：青光眼长期治疗取得新进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=141116545004)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993316, encodeId=13461993316b2, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=2019年ARVO：Tocilizumab显著减少巨细胞动脉炎的发作次数, objectType=article, longId=165390, objectId=1e7e16539077, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e7e16539077, replyNumber=0, likeNumber=80, createdTime=2020-01-15, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e7e16539077, moduleTitle=2019年ARVO：Tocilizumab显著减少巨细胞动脉炎的发作次数, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1e7e16539077)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993315, encodeId=d72e199331532, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=ARVO年会干货眼科研究都在这里, objectType=article, longId=139503, objectId=ced3139503aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced3139503aa, replyNumber=0, likeNumber=80, createdTime=2018-11-27, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced3139503aa, moduleTitle=ARVO年会干货眼科研究都在这里, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ced3139503aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993314, encodeId=f7371993314e5, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=AIM：Harvoni治疗HCV感染的肾移植受者的疗效研究, objectType=article, longId=82664, objectId=cb7b82664df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb7b82664df, replyNumber=0, likeNumber=88, createdTime=2017-02-07, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb7b82664df, moduleTitle=AIM：Harvoni治疗HCV感染的肾移植受者的疗效研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=cb7b82664df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993313, encodeId=ea2619933134d, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=ARVO 2016：角膜内皮营养不良及抗角膜新生血管治疗的前沿热点, objectType=article, longId=71240, objectId=7791e12402a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7791e12402a, replyNumber=0, likeNumber=78, createdTime=2017-05-31, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7791e12402a, moduleTitle=ARVO 2016：角膜内皮营养不良及抗角膜新生血管治疗的前沿热点, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7791e12402a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993310, encodeId=db411993310d1, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=ILC 2016：Harvoni治疗肾移植的HCV患者仍安全有效, objectType=article, longId=66808, objectId=a992668086e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a992668086e, replyNumber=0, likeNumber=89, createdTime=2016-06-27, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a992668086e, moduleTitle=ILC 2016：Harvoni治疗肾移植的HCV患者仍安全有效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a992668086e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993311, encodeId=95901993311af, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=ARVO 2016：无眼部病变但是高度近视的患者也会出现轻度视觉障碍, objectType=article, longId=67774, objectId=28376e774e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28376e774e0, replyNumber=0, likeNumber=82, createdTime=2016-09-17, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28376e774e0, moduleTitle=ARVO 2016：无眼部病变但是高度近视的患者也会出现轻度视觉障碍, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=28376e774e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993312, encodeId=763e1993312a5, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=ARVO 2016：低水平的维生素D与非感染性葡萄膜炎的发生有关, objectType=article, longId=67777, objectId=4eef6e777a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eef6e777a3, replyNumber=0, likeNumber=71, createdTime=2016-09-21, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eef6e777a3, moduleTitle=ARVO 2016：低水平的维生素D与非感染性葡萄膜炎的发生有关, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4eef6e777a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993309, encodeId=d32e199330972, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=ILC 2016：Harvoni对青少年HCV依然高度有效, objectType=article, longId=66615, objectId=688a6661543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=688a6661543, replyNumber=0, likeNumber=66, createdTime=2017-03-09, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=688a6661543, moduleTitle=ILC 2016：Harvoni对青少年HCV依然高度有效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=688a6661543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993307, encodeId=30ba199330e76, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=喜大普奔！吉利德丙肝鸡尾酒Harvoni获FDA批准！, objectType=article, longId=41187, objectId=3e0f4118ec0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e0f4118ec0, replyNumber=0, likeNumber=71, createdTime=2015-02-06, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e0f4118ec0, moduleTitle=喜大普奔！吉利德丙肝鸡尾酒Harvoni获FDA批准！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3e0f4118ec0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993308, encodeId=a550199330867, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=吉利德丙肝药物Harvoni获欧盟上市许可, objectType=article, longId=43045, objectId=f673430454f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f673430454f, replyNumber=0, likeNumber=84, createdTime=2014-12-11, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f673430454f, moduleTitle=吉利德丙肝药物Harvoni获欧盟上市许可, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f673430454f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993306, encodeId=b2c11993306f7, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, objectTitle=ARVO 2013：热点回顾之视网膜, objectType=article, longId=20367, objectId=ff192036e48, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff192036e48, replyNumber=0, likeNumber=76, createdTime=2013-09-16, rootId=0, userName=12498da4m32(暂无昵称), userId=636e2500187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff192036e48, moduleTitle=ARVO 2013：热点回顾之视网膜, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ff192036e48)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

ARVO

2020-05-29

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

辉瑞的DMD基因疗法fordadistrogene movaparvovec在患者死亡后被FDA搁置

2022-04-03

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验

2022-01-18

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

基因疗法Valoctocogene Roxaparvovec治疗严重血友病A：长期数据再次验证有效性和安全性

2021-04-19

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

WFH 2020：四年数据显示，A型血友病基因疗法valoctocogene roxaparvovec可持续减少出血

2021-02-15

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

2019年ARVO：Aflibercept能够长期改善黄斑变性的临床症状

2019-07-11

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

2019年ARVO：青光眼长期治疗取得新进展

2019-06-05

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

2019年ARVO：Tocilizumab显著减少巨细胞动脉炎的发作次数

2020-01-15

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

ARVO年会干货眼科研究都在这里

2018-11-27

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

AIM：Harvoni治疗HCV感染的肾移植受者的疗效研究

2017-02-07

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

ARVO 2016：角膜内皮营养不良及抗角膜新生血管治疗的前沿热点

2017-05-31

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

ILC 2016：Harvoni治疗肾移植的HCV患者仍安全有效

2016-06-27

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

ARVO 2016：无眼部病变但是高度近视的患者也会出现轻度视觉障碍

2016-09-17

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

ARVO 2016：低水平的维生素D与非感染性葡萄膜炎的发生有关

2016-09-21

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

ILC 2016：Harvoni对青少年HCV依然高度有效

2017-03-09

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

喜大普奔！吉利德丙肝鸡尾酒Harvoni获FDA批准！

2015-02-06

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

吉利德丙肝药物Harvoni获欧盟上市许可

2014-12-11

12498da4m32(暂无昵称) (审核中...)

前往app查看评论内容

#ARVO#

ARVO 2013：热点回顾之视网膜

2013-09-16

科室
- - 订阅+
  - 更多科室
工具
服务